C12N 2840/20
Translation of more than one cistron
Official title: translation of more than one cistron
C12N2840/20 (Translation of more than one cistron) appears on 1,169 US grants and 1,838 published applications in this corpus.
Search patents in C12N- Granted patents
- 1,169
- Published applications
- 1,838
- Assignees
- 776
- Inventors
- 3,288
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 1 | 0 |
| 1993 | 2 | 0 |
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 16 | 0 |
| 1997 | 24 | 0 |
| 1998 | 41 | 0 |
| 1999 | 29 | 0 |
| 2000 | 45 | 0 |
| 2001 | 49 | 14 |
| 2002 | 50 | 95 |
| 2003 | 57 | 180 |
| 2004 | 45 | 149 |
| 2005 | 39 | 130 |
| 2006 | 52 | 116 |
| 2007 | 57 | 63 |
| 2008 | 52 | 70 |
| 2009 | 44 | 71 |
| 2010 | 45 | 69 |
| 2011 | 48 | 68 |
| 2012 | 40 | 59 |
| 2013 | 50 | 36 |
| 2014 | 40 | 40 |
| 2015 | 30 | 32 |
| 2016 | 36 | 46 |
| 2017 | 31 | 53 |
| 2018 | 31 | 45 |
| 2019 | 22 | 44 |
| 2020 | 36 | 38 |
| 2021 | 36 | 59 |
| 2022 | 23 | 69 |
| 2023 | 24 | 71 |
| 2024 | 22 | 71 |
| 2025 | 32 | 73 |
| 2026 | 16 | 77 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Chimeric antigen receptors with CD20 safety switch22 Sep 2026US 12,742,001 B2St. Jude Children?S Research Hospital
- Integration of nucleic acid constructs into eukaryotic cells with a transposase from oryzias22 Sep 2026US 12,742,171 B2Dna Twopointo Inc.
- Multi-transgenic pig for Xenotransplantation25 Aug 2026US 12,714,077 B2Revivicor, Inc.
- Protein heterodimer and use thereof18 Aug 2026US 12,709,638 B2Ningbo Innovative Mechanism Bioscience LLC
- Multitransgenic pigs comprising ten genetic modifications for xenotransplantation9 Jun 2026US 12,648,548 B2Revivicor, Inc.
- Vaccine Adjuvants8 Oct 2026US 2026/0306623 A1Seqirus Inc.
- Adenovirus vector circular rna expression system8 Oct 2026US 2026/0306666 A1
- Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene8 Oct 2026US 2026/0308549 A1Precision BioSciences, Inc.
- Method8 Oct 2026US 2026/0308574 A1Sania Tx Ltd
- Viral vectors for cell therapy1 Oct 2026US 2026/0294971 A1
Most cited
By later US patents
- Genetic constructs for delaying or repressing the expression of a target gene369US 6,573,099 B2Benitec Australia Limited · 2003
- AAV-mediated delivery of DNA to cells of the nervous system222US 6,180,613 B2The Rockefeller University · 2001
- Recombinant negative strand RNA virus expression-systems218US 5,166,057 AMount Sinai School of Medicine of the City University of New York · 1992
- Eukaryotic layered vector initiation systems204US 5,814,482 A1998
- Stocks of recombinant, replication-deficient adenovirus free of replication-competent adenovirus184US 5,994,106 AGenVec, Inc. · 1999